"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

n=8), weekly exenatide injections (Bydureon BCise®, n=8), or weekly 1 mg semaglutide injections (Wegovy®, n=8) for a 9-week treatment duration. Changes in weight will be measured. The study is ...

Objective–To investigate the effect of treatment with the glucagon-like peptide 1 receptor agonist exenatide on weight loss and metabolic parameters in obese nondiabetic women. Research Design ...

Another trial investigating exenatide (another GLP-1 agonist) also found reduced alcohol consumption and improved metabolic health outcomes (Goudriaan et al., 2022). These results support the ...

At the same time, it reduced the prevalence of inflammation-associated microbes. Exenatide and exendin-4 showed similar benefits in animal studies, enhancing populations of Akkermansia and ...

The treatments, which include medications like semaglutide, liraglutide and exenatide, have been linked to a slightly reduced dementia risk before, but this was based on observational studies ...

Individuals living with prediabetes are less at risk of going on to develop type 2 diabetes if they follow a digital lifestyle programme, recent research has demonstrated. A new study has found that ...

Restricting your carbohydrate intake can “reap the metabolic effects associated with short-term fasting”, a new study has revealed. Researchers from the University of Surrey have found that limiting ...

Orforglipron, Eli Lilly’s investigational oral glucagon-like peptide 1 receptor agonist (GLP-1 RA), achieved positive phase 3 results for both A1c and weight loss, according to top-line data ...